A Double-Blind, Multicenter, Placebo-Controlled, Randomized, Parallel, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants
Latest Information Update: 04 May 2022
At a glance
- Drugs Pegbelfermin (Primary)
- Indications Fibrosis; Liver disorders; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 25 Apr 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Jun 2021 Planned initiation date changed from 15 Dec 2020 to 21 Jun 2021.
- 28 May 2021 Planned End Date changed from 9 Apr 2021 to 22 Sep 2021.